Table 2.
SARS-CoV-2 IgM and/or IgG positivity percentages of patients (divided into oncology units) and healthcare providers
| Oncology unit category | Treatment | Number of patients | IgM and IgG negative | IgM and/or IgG positive | p-value | ||
|---|---|---|---|---|---|---|---|
| Number of patients | Percentage of patients | Number of patients | Percentage of patients | ||||
| Melanoma | ICIs | 287 | 278 | 96.9 | 9 | 3.1 | – |
| Breast | CHTs | 183 | 165 | 90.2 | 18 | 9.8 | – |
| Thoraco-pulmonary | CHTs | 16 | 15 | 93.8 | 1 | 6.3 | |
| Uro-gynaecological | CHTs | 118 | 114 | 96.6 | 4 | 3.4 | |
| Head-neck | CHTs | 16 | 16 | 100.0 | 0 | 0.0 | |
| Sarcoma | CHTs | 30 | 27 | 90.0 | 3 | 10.0 | |
| Gastro-intestinal | CHTs | 235 | 222 | 94.47 | 13 | 5.5 | |
| Total CHTs “non melanoma” patients | CHTs | 598 | 559 | 93.5 | 39 | 6.5 | 0.04* |
| Category | Number of cases | IgM and IgG negative | IgM and/or IgG positive | p-value | ||
|---|---|---|---|---|---|---|
| Number of subjects | Percentage of subjects | Number of subjects | Percentage of subjects | |||
| Healthcare providers | 1050 | 1002 | 95.4 | 48 | 4.6 | 0.29** |
ICIs Immune Checkpoint Inhibitors Treatment, CHTs chemotherapy treatments
*Comparison ICIs vs. CHTs patients’ SARS-CoV-2 IgM and/or IgG positivity percentages (statistically significant) (Pearson’s χ2 test was used to identify differences in the proportions of individuals between two categories)
**Comparison ICIs patients’ vs. Healthcare Providers’ SARS-CoV-2 IgM and/or IgG positivity percentages (not statistically significant) (Pearson’s χ2 test was used to identify differences in the proportions of individuals between two categories)